Stereotactic body radiation therapy for early-stage lung cancer: are we 'all in'.

摘要

Stereotactic body radiation therapy (SBRT) has rapidly been adopted into clinical practice as an option for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC) based on reports of excellent outcomes, often with local tumor control >90%, from centers in North America, Europe, and Asia. Although data for metastatic lung tumors are less robust, experience supporting SBRT as a viable alternative to surgical resection in this patient population is growing, and Siva et al.provide a comprehensive review of SBRT for pulmonary (oligo) metastases in this issue of the journal. They conclude that SBRT seems both effective and safe in the metastatic setting as a 2-year local tumor control approached 80%, whereas severe toxicity was observed in less than 5% of patients.